TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05040841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S2/Peer: Enhanced peer group support
Description: Subject will receive an enhanced form of peer group support. Standard of care Basic peer groups are led by lay counsellors and provide social support and education; this will continue to be provided to all patients who are not assigned to the enhanced version. Enhanced peer group support will replace the Basic standard of care 4 x 60 minute peer groups; and aim to improve long-term maintenance of adherence through motivational interviewing over 4-8 weeks.
Study: NCT05514691

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: iStatis COVID-19 Ag Rapid Test
Description: SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America (Labcorp)
Description: The Labcorp COVID-19 RT-PCR or EURORealTime SARS-Cov-2 tests are performed on all appropriate swab samples from each subject enrolled as a comparator test to iStatis Rapid Test
Study: NCT05620550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ozonated oil
Description: Post operative scar treatment with ozonated oil

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non ozonated oil
Description: Post operative scar treatment with non ozonated oil
Study: NCT04516993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: The best treatment selected by local doctors(Aspirin, Recombinant Tissue Plasminogen Activator, Urokinase, Thrombectomy)
Description: Best treatment arm
Study: NCT06377254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decreased Physical Activity
Description: Physical activity levels will be decreased

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased Physical activity
Description: Physical activity levels will be increased
Study: NCT04630418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NanoSilk Cosmo
Description: Participant will receive 30 mL of NanoSilk Cosmo jar.
Study: NCT05346159

Intervention type: DIAGNOSTIC_TEST
Intervention: the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS
Description: Laboratory assessment Serum dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) will be measured using an enzyme mediated chemiluminescence for all participants Gender-typed behavior assessment~* Parents of girls aged two to six years will evaluate their children's gender-typed behavior using the Pre school Activities Inventory~* For girls above 6 years gender characteristics and gender role behavior will be evaluated using The Children's Sex Role Inventory (Child-adapted version of the original Bem Sex Role Inventory)~* For all participants a Parent-Report Gender Identity Questionnaire for Children will be used to evaluate gender role behavior

Intervention type: DIAGNOSTIC_TEST
Intervention: the correlation between level of adrenal androgen and gender-typed behavior in Girls with TS
Description: Laboratory assessment Serum dehydroepiandrosterone sulfate (DHEAS), follicle stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) will be measured using an enzyme mediated chemiluminescence for all participants Gender-typed behavior assessment~* Parents of girls aged two to six years will evaluate their children's gender-typed behavior using the Pre school Activities Inventory~* For girls above 6 years gender characteristics and gender role behavior will be evaluated using The Children's Sex Role Inventory (Child-adapted version of the original Bem Sex Role Inventory)~* For all participants a Parent-Report Gender Identity Questionnaire for Children will be used to evaluate gender role behavior
Study: NCT05870709

Intervention type: OTHER
Intervention: sacubitril/valsartan
Description: There is no treatment allocation. Patients with a first ambulatory sacubitril/valsartan prescription who are interested in study participation will be enrolled.
Study: NCT05555212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLH11811
Description: In Ia phase, subjects will first receive oral single dose of QLH11811, then will be observed for 7 days. If the drug is tolerated by the subjects, the subjects will continue to receive the oral repeat dose of QLH11811 for 21 consecutive days. Upon the completion of observation for DLT in the subjects (DLT observation period is the 28 days after the first dose), the subjects will continue to receive the repeat dose of QLH11811 in Cycle 2 and subsequent cycles. The dosing frequency in Cycle 2 and subsequent cycles is once daily, and each cycle has 3 weeks.~The RP2D of QLH11811 is determined on the basis of comprehensive evaluation of all safety and tolerability data and all available PK, PD and efficacy data during the dose escalation phase. In phase 1b, the cohort expansion study is carried out for all cohorts in China and the United States concurrently according to the determined RP2D.
Study: NCT06320795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOUNDI
Description: Continuous monitoring of vital signs for diagnosis and follow-up of sleep-disordered breathing in adults.
Study: NCT05939375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCC educational training
Description: An educational training, grounded in six weeks of nurse-centered interactions, was implemented.
Study: NCT05933512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E-2
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E-2
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTV01E
Description: intramuscular injection
Study: NCT04562597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Reduction with Optimal N-acetylcysteine Dose
Description: Once the optimal N-acetylcysteinedose is identified, 15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.
Study: NCT06153511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot assisted spinal transpedicular fixation
Description: Surgical technique which joins two or more vetebrae with screws and rods to prevent any relative movement between them. It is a major surgery that usually lasts several hours and in which the patient is subjected to general anesthesia. The screws to be placed go through a narrow area of the vertebra known as the pedicle. Each patient will undergo a singular intervention.
Study: NCT05692765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone application to enhance fruit and vegetables intake among adolescents
Description: This randomized intervention study was conducted in an urban area of Jeddah, Saudi Arabia. We included 104 adolescents aged 13-18 years, who were randomized into intervention (n=55) or control (n=49) arms. We examined the effects of a smartphone application (My Plate) on fruit and vegetable intake over 6 weeks in the intervention group. Pre- and postintervention questionnaires were used in the intervention and control groups.
Study: NCT05767892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK-209A tablet
Description: YK-029A 200 milligram (mg) , orally without food，once daily until the participants experience PD as assessed by blinded IRC, intolerable toxicity, or another discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed+carboplatin/Cisplatin
Description: Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
Study: NCT04691284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood, urine and stool sampling
Description: Sampling of blood and urine for miR and chemokine detection. Sampling of stool for for microbiome studies.
Study: NCT06313970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 5mg/kg，IV，D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 5mg/kg，IV，D1, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine，1000mg/m2，IV，D1、8；Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine，1000mg/m2，IV，D1、8；Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab, 7.5mg/kg，IV，D1；Q3W.
Study: NCT06176573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Pre-operative and post-operative vaginal cleansing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Pre-operative and post-operative vaginal cleansing.
Study: NCT05878054

Intervention type: OTHER
Group type: OTHER
Intervention: Proactive, integrated and personalised care
Description: During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.

Intervention type: OTHER
Group type: OTHER
Intervention: Proactive, integrated and personalised care
Description: During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.

Intervention type: OTHER
Group type: OTHER
Intervention: Proactive, integrated and personalised care
Description: During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.

Intervention type: OTHER
Group type: OTHER
Intervention: Proactive, integrated and personalised care
Description: During the intervention patients receive proactive, integrated and personalised care. An intake consultation using Positive Health tool, or a similar method, the needs of each patient is assessed. In a multidisciplinary meeting with the GP, mental health care practice nurse, a social worker and the patient, a personalised care plan is made. The personal is executed and a care coordinator maintains proactive contact with the patient. Clinical follow-up will be done via a second multidisciplinary meeting.
Study: NCT05474742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Nori Health app
Description: The Nori Health app consist of a chatbot that instantly answers questions about topics relevant to patients with IBD and 6-week education program. The chatbot is driven by artificial intelligence and armed with state of the art scientific literature to offer to the right information to the right person at the right time. The education program is offered during the first six weeks of use. The Nori Health app then actively offers information on four fixed topics and two topics to a participant's choosing (i.e. low energy, pain, stress, mental health, hydration, exercising). It is expected from participants that they respond to this by having approximately five chat conversations of five minutes per week. Participants in the intervention group receive access to the Nori Health app for a 6-month period directly after randomization. They are free to use the Nori Health app whenever and as often as they want. Participants in the control group receive no intervention.
Study: NCT04952142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minimal water exchange
Description: Use a new technique, minimal water exchange colonoscopy, which adds the infusion of modest amounts of water by constant pressure on the air-water valve button of the endoscope to achieve intubation.
Study: NCT05687422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 100μm laser spot diameter micropulse laser
Description: 100μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 200μm laser spot diameter micropulse laser
Description: 200μm laser spot diameter micropulse laser at baseline, then follow-up for 6 months
Study: NCT05624203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiac shock wave therapy(ECSW)
Description: Extracorporeal cardiac shock wave therapy (CSWT) is a cutting-edge technology developed in the world for more than 20 years. It is mainly used in the treatment of refractory angina pectoris of coronary heart disease. The mechanism of extracorporeal cardiac shock wave therapy is mainly due to the small attenuation, small shear stress and strong penetration force of shock wave when propagating in human tissues. Shear stress and hole effect are generated in the focal area of shock wave, which leads to the repeated formation/rupture of microbubbles in tissue/cell microenvironment, resulting in various physical and biological effects. These physical mechanisms trigger a series of biological effects, such as promoting the expression of various intracellular cytokines and angiogenic factors, activating related signal transduction pathways, inhibiting apoptosis and oxidative stress, and finally increasing the number of new blood vessels in the treatment area and improving the ischemic state.
Study: NCT05587205

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EO2002
Description: Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2002
Description: Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2002
Description: Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection
Study: NCT04866160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06427239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab will be administrated per dose level in which the patients are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab will be administrated per dose level in which the patients are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab will be administrated per dose level in which the patients are assigned
Study: NCT04419779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing (DMR)
Description: The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Duodenal Mucosal Resurfacing (Sham)
Description: The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 48 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
Study: NCT06149117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®
Description: Take one capsule orally every cycle(T or R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®
Description: Take one capsule orally every cycle(T or R)
Study: NCT05819073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain water
Description: Subjects will use plain water as an oral rinse twice a day for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plain water
Description: Subjects will use plain water as an oral rinse twice a day for 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPE
Description: Subjects will use a cranberry-derived oral rinse twice a day for 11 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPE
Description: Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
Study: NCT04888052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute ACL injury
Description: Quantification of the preoperative deficits, by an isokinetic dynamometer, in order to adapt the care management of patients found with a muscle deficiency. Patients with preoperative knee extensor deficits \> 15% will benefit from an additional preoperative rehabilitation protocol (8 weeks).
Study: NCT04609787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: Participants are placed in three-dimensional, life-sized computer-generated environments via a computer headset shows potential as a treatment for chronic pain and central sensitization.
Study: NCT05248841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC-Glargine
Description: Subjects will receive 0.5 IU/kg of HEC-Glargine subcutaneously as a single morning dose on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-Lantus
Description: Subjects will receive 0.5 IU/kg of Lantus subcutaneously as a single morning dose on Day 1.
Study: NCT04526145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and emotion management
Description: Group intervention led by a nurse and dietitian to address stress, emotion management and healthy lifestyle for African American women with hypertension. The weekly sessions will include:how to manage stress during Covid-19, taking blood pressure, interpersonal relationships skills, mindful awareness, restful sleep, physical activity, and healthy eating.
Study: NCT04526717

Intervention type: DRUG
Group type: OTHER
Intervention: MPT0B640
Description: Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640)
Study: NCT05466500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided axillary block with intravenous dexamethasone
Description: it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine plus 0.1mg/kg dexamethasone intravenous

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound guided axillary block
Description: it will be given by one researcher using 2 mg/kg of 0.25% bupivacaine